Join Medicilon at BIO KOREA 2022: Beyond the Pandemic, into A Next Wave

BIO KOREA 2022 International Convention is only one week to go! Medicilon is excited to exhibit in the conference. Our Korean Business Team will be waiting at booth D11. Please stop by and explore our services and capabilities. We look forward to seeing you soon and wish you the safe trips!

Date: May 11(Wed) - 13(Fri), 2022

Location: COEX, Seoul

Booth: D11

ABOUT BIO KOREA

BIO KOREA has been held every year since 2006 and serves as a business platform for international biohealth companies. Sponsored by the Ministry of Health and Welfare, BIO KOREA is a place of practical business correspondence as well as international information and technology exchange, invigorating the biohealth industry. In its 17th year of bringing together various international academics, professionals, and CEOs of global biohealth companies to obtain, exchange, and discuss diverse affairs, through exhibition, business forum, and conference.

ABOUT Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world.

Innovative Drug R&D Services

Antibody-Drug Conjugate (ADC)

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

Proteolysis Targeting Chimera (PROTAC) 

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines.  We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.

AI R&D Innovation

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

#PROTAC #AI #drugdiscovery